IL7R and myeloid sarcoma: Our results demonstrated a significant down-regulation of IL7R in sporadic MS patients compared with the control group by 80% ± 0.4515 (Pvalue < 0.0001) as well as the FDR group by 59% ± 0.4478 (Pvalue = 0.0005).